Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER

Name: .....

Ward: .....

PATIENT:

Name: .....

NHI: .....

Everolimus

INITIATION
Re-assessment required after 3 months
Prerequisites (tick boxes where appropriate)

- ○ Prescribed by, or recommended by a neurologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ○ Patient has tuberous sclerosis

and

- ○ Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment

CONTINUATION
Re-assessment required after 12 months
Prerequisites (tick boxes where appropriate)

- ○ Prescribed by, or recommended by a neurologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ○ Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months

and

- ○ The treatment remains appropriate and the patient is benefiting from treatment

and

- ○ Everolimus to be discontinued at progression of SEGAs

INITIATION – renal cell carcinoma
Re-assessment required after 4 months
Prerequisites (tick boxes where appropriate)

- ○ The patient has metastatic renal cell carcinoma

and

- ○ The disease is of predominant clear-cell histology

and

- ○ The patient has documented disease progression following one previous line of treatment

and

- ○ The patient has an ECOG performance status of 0-2

and

- ○ Everolimus is to be used in combination with lenvatinib

or

- ○ Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma

and

- ○ Patient has experienced treatment limiting toxicity from treatment with nivolumab

and

- ○ Everolimus is to be used in combination with lenvatinib

and

- ○ There is no evidence of disease progression

CONTINUATION – renal cell carcinoma
Re-assessment required after 4 months
Prerequisites (tick box where appropriate)

- ○ There is no evidence of disease progression

I confirm that the above details are correct:

Signed: ..... Date: .....